AU Patent

AU2019240616A1 — N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

Assigned to Kalvista Pharmaceuticals Ltd · Expires 2019-10-17 · 7y expired

What this patent protects

C:\Interwo n\NRPortbl\DCC\SXD\19372483_I.docx-I/l0/2019 The present invention provides compounds of formula (1): (1) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma …

USPTO Abstract

C:\Interwo n\NRPortbl\DCC\SXD\19372483_I.docx-I/l0/2019 The present invention provides compounds of formula (1): (1) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein. ' H O\B

Drugs covered by this patent

Patent Metadata

Patent number
AU2019240616A1
Jurisdiction
AU
Classification
—
Expires
2019-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Kalvista Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.